Neo-adjuvant Pembrolizumab in dMMR/ POLE-EDM Uterine Cancer Patients: a Feasibility Study
Status:
Recruiting
Trial end date:
2022-11-01
Target enrollment:
Participant gender:
Summary
In this feasibility study the investigators intend to treat patients with high mutational
uterine cancer with two cycles immune checkpoint inhibition before standard-of-care
hysterectomy.